NCT04501796View on ClinicalTrials.gov

A Trial of NT-I7 in COVID-19 (SPESELPIS)

PHASE1TerminatedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

July 21, 2021

Study Completion Date

February 23, 2023

Conditions

COVID-19

Interventions

DRUG

Double-Blind NT-I7

Administered by intramuscular (IM) injection

DRUG

Double-Blind Placebo

Placebo

Trial Locations (2)

20892

Nih/Niaid, Bethesda

68198

University of Nebraska Medical Center, Omaha

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

University of Nebraska

OTHER

lead

NeoImmuneTech

INDUSTRY